Frankfurt
15.12.25 | 15:29
6,400 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | FDA sets new PDUFA date for Fortress Biotech's Menkes disease therapy | 17 | Investing.com | ||
| Mo | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11. | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 557 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 14.11. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.11. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Fortress Biotech Q3 Earnings Preview | 5 | Seeking Alpha | ||
| 21.10. | Fortress Biotech: Aktie legt zu - Gichtmittel der Tochtergesellschaft erreicht Phase-3-Studie | 14 | Investing.com Deutsch | ||
| 21.10. | Fortress Biotech stock rises after subsidiary's gout treatment enters Phase 3 trials | 2 | Investing.com | ||
| 21.10. | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 208 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 02.10. | FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln | 19 | Investing.com Deutsch | ||
| 02.10. | Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101 | 3 | Investing.com | ||
| 01.10. | Fortress Biotech stock plummets after FDA rejects Menkes disease drug | 13 | Investing.com | ||
| 01.10. | Fortress Biotech plunges as FDA rejects rare disease drug | 20 | Seeking Alpha | ||
| 01.10. | Fortress Biotech, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.10. | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 118 | GlobeNewswire (Europe) |
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| 01.10. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 156 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen | |
| 21.08. | Fortress Biotech stock price target lowered to $17 at H.C. Wainwright | 26 | Investing.com | ||
| 14.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 469 | GlobeNewswire (Europe) | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| 16.07. | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 299,40 | -1,09 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| REGENERON PHARMACEUTICALS | 640,40 | 0,00 % | 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow | ||
| VIKING THERAPEUTICS | 31,210 | +1,36 % | This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street | ||
| INTELLIA THERAPEUTICS | 7,692 | -1,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 59,00 | +0,85 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| NUREXONE BIOLOGIC | 0,439 | +3,05 % | Starkes drittes Quartal 2025: NurExone erzielt wissenschaftliche Fortschritte und Kapitalzufluss | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,748 | -3,36 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,900 | +7,48 % | Ginkgo Bioworks kooperiert mit Deep Origin bei ARPA-H-Projekt zur Arzneimittelsicherheit | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Why Recursion Pharamaceuticals Topped the Market Today | ||
| IOVANCE BIOTHERAPEUTICS | 1,830 | -0,22 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,554 | +1,48 % | CytomX-Aktie nach +1.000% - was jetzt? | Unser Community-Dauerbrenner CytomX Therapeutics hat sich seit unserem letzten Update Anfang Oktober weiter hervorragend entwickelt, konnte sich innerhalb eines Jahres mittlerweile verzehnfachen. Ist... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,080 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| BIOMEA FUSION | 1,345 | -4,61 % | Biomea Fusion, Inc.: Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 | ||
| TERNS PHARMACEUTICALS | 37,400 | 0,00 % | Terns Pharmaceuticals, Inc.: Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its... ► Artikel lesen | |
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.